VALN vs. VCEL, IMCR, ADMA, CGON, RXRX, NVAX, KYMR, BEAM, FUSN, and INBX
Should you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Vericel (VCEL), Immunocore (IMCR), ADMA Biologics (ADMA), CG Oncology (CGON), Recursion Pharmaceuticals (RXRX), Novavax (NVAX), Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), and Inhibrx (INBX). These companies are all part of the "biological products, except diagnostic" industry.
Vericel (NASDAQ:VCEL) and Valneva (NASDAQ:VALN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership, dividends and community ranking.
In the previous week, Valneva had 2 more articles in the media than Vericel. MarketBeat recorded 7 mentions for Valneva and 5 mentions for Vericel. Valneva's average media sentiment score of 0.86 beat Vericel's score of 0.34 indicating that Vericel is being referred to more favorably in the media.
Vericel has higher revenue and earnings than Valneva. Vericel is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.
Vericel has a net margin of 0.22% compared to Vericel's net margin of -15.88%. Valneva's return on equity of 0.21% beat Vericel's return on equity.
11.4% of Valneva shares are owned by institutional investors. 7.2% of Vericel shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Vericel has a beta of 1.74, meaning that its share price is 74% more volatile than the S&P 500. Comparatively, Valneva has a beta of 2.22, meaning that its share price is 122% more volatile than the S&P 500.
Vericel presently has a consensus price target of $46.80, suggesting a potential downside of 2.44%. Valneva has a consensus price target of $21.67, suggesting a potential upside of 150.42%. Given Vericel's higher possible upside, analysts plainly believe Valneva is more favorable than Vericel.
Vericel received 312 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 62.11% of users gave Vericel an outperform vote while only 53.33% of users gave Valneva an outperform vote.
Summary
Vericel beats Valneva on 11 of the 17 factors compared between the two stocks.
Get Valneva News Delivered to You Automatically
Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
